Liver Cancer - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Liver Cancer > What Your Doctor is Reading About Liver Cancer > Clinical Trials

Clinical Trials

1. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.

Author: Butterfield LH; Ribas A; Dissette VB; Lee Y; Yang JQ; De la Rocha P; Duran SD; Hernandez J; Seja E; Potter DM; McBride WH; Finn R; Glaspy JA; Economou JS;
Institution: Department of Medicine, Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA. butterfield@upmc.edu
Journal: Clin Cancer Res. 2006 May 1;12(9):2817-25.
Abstract URL: Click here to view abstract

2. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.

Author: Chen ZN; Mi L; Xu J; Song F; Zhang Q; Zhang Z; Xing JL; Bian HJ; Jiang JL; Wang XH; Shang P; Qian AR; Zhang SH; Li L; Li Y; Feng Q; Yu XL; Feng Y; Yang XM; Tian R; Wu ZB; Leng N; Mo TS; Kuang AR; Tan TZ; Li YC; Liang DR; Lu WS; Miao J; Xu GH; Zhang ZH; Nan KJ; Han J; Liu QG; Zhang HX; Zhu P;
Institution: Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China.
Journal: Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):435-44.
Abstract URL: Click here to view abstract

3. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.

Author: Kim SJ; Seo HY; Choi JG; Sul HR; Sung HJ; Park KH; Choi IK; Oh SC; Yoon SY; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS;
Institution: Division of Hematology/Oncology Department of Internal Medicine, Korea University Medical Center, 126-1, Anam-dong 5-ga, Sungbuk-ku, Seoul, 136-705, Korea.
Journal: Cancer Chemother Pharmacol. 2006 Apr;57(4):436-42. Epub 2005 Jul 28.
Abstract URL: Click here to view abstract

4. Survival of patients with early hepatocellular carcinoma treated by percutaneous alcohol injection.

Author: Andriulli A; De Sio I; Brunello F; Salmi A; Solmi L; Facciorusso D; Caturelli E; Perri F;
Institution: Department of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy. a.andriulli@operapadrepio.it
Journal: Aliment Pharmacol Ther. 2006 May 1;23(9):1329-35.
Abstract URL: Click here to view abstract

5. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children.

Author: Czauderna P; Zbrzezniak G; Narozanski W; Korzon M; Wyszomirska M; Stoba C;
Institution: Department of Pediatric Surgery, Medical University of Gdansk, Gdansk, Poland. pczaud@amg.gda.pl
Journal: Pediatr Blood Cancer. 2006 Jun;46(7):825-8.
Abstract URL: Click here to view abstract

6. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.

Author: Obi S; Yoshida H; Toune R; Unuma T; Kanda M; Sato S; Tateishi R; Teratani T; Shiina S; Omata M;
Institution: Department of Hepatology, Kyoundo Hospital, Tokyo, Japan. obi-shun@imail.plala.or.jp
Journal: Cancer. 2006 May 1;106(9):1990-7.
Abstract URL: Click here to view abstract

7. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.

Author: Chen MS; Li JQ; Zheng Y; Guo RP; Liang HH; Zhang YQ; Lin XJ; Lau WY;
Institution: Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, Guangzhou, China. Cms64@21cn.com
Journal: Ann Surg. 2006 Mar;243(3):321-8.
Abstract URL: Click here to view abstract

8. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.

Author: Hsu WC; Chan SC; Ting LL; Chung NN; Wang PM; Ying KS; Shin JS; Chao CJ; Lin GD;
Institution: Department of Radiation Oncology, Cheng-Ching General Hospital, Taichung, Taiwan.
Journal: Jpn J Clin Oncol. 2006 Feb;36(2):93-9.
Abstract URL: Click here to view abstract

9. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization.

Author: Jang JW; Choi JY; Bae SH; Yoon SK; Chang UI; Kim CW; Cho SH; Han JY; Lee YS;
Institution: Department of Internal Medicine, College of Medicine, WHO Collaborating Center on Viral Hepatitis, The Catholic University of Korea, Seoul, Korea.
Journal: Hepatology. 2006 Feb;43(2):233-40.
Abstract URL: Click here to view abstract

10. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial.

Author: Kirchhoff TD; Rudolph KL; Layer G; Chavan A; Greten TF; Rosenthal H; Kubicka S; Galanski M; Manns MP; Schild H; Gallkowski U;
Institution: Department of Diagnostic Radiology, Hannover Medical School, OE 8220, D-30625 Hannover, and Department of Radiology, University Hospital, Bonn, Germany. kirchhoff.timm@mh-hannover.de
Journal: Eur J Surg Oncol. 2006 Mar;32(2):201-7. Epub 2005 Dec 20.
Abstract URL: Click here to view abstract

11. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.

Author: Boige V; Taieb J; Hebbar M; Malka D; Debaere T; Hannoun L; Magherini E; Mignard D; Poynard T; Ducreux M;
Institution: Gastrointestinal Oncology Unit, Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France. boige@igr.fr
Journal: Eur J Cancer. 2006 Mar;42(4):456-9. Epub 2006 Jan 20.
Abstract URL: Click here to view abstract

12. Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma.

Author: Kim JK; Han KH; Lee JT; Paik YH; Ahn SH; Lee JD; Lee KS; Chon CY; Moon YM;
Institution: Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei Liver Cancer Study Group, Yonsei University College of Medicine, 134 Shinchoin-dong, Seodaemoon-gu, Seoul, Korea 120-752.
Journal: Clin Cancer Res. 2006 Jan 15;12(2):543-8.
Abstract URL: Click here to view abstract

13. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients.

Author: Kasugai H; Osaki Y; Oka H; Kudo M; Seki T;
Institution: Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. kasugai-hi@mc.pref.osaka.jp
Journal: Oncology. 2007;72 Suppl 1:72-5. Epub 2007 Dec 13.
Abstract URL: Click here to view abstract

14. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

Author: Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K;
Institution: Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. jfuruse@east.ncc.go.jp
Journal: Cancer Sci. 2008 Jan;99(1):159-65. Epub 2007 Oct 22.
Abstract URL: Click here to view abstract

15. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

Author: Livraghi T; Meloni F; Di Stasi M; Rolle E; Solbiati L; Tinelli C; Rossi S;
Institution: Department of Radiology, Ospedale Civile, Vimercate, Milano, Italy. tito.livraghi@aovimercate.org
Journal: Hepatology. 2008 Jan;47(1):82-9.
Abstract URL: Click here to view abstract

16. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

Author: Thomas MB; Chadha R; Glover K; Wang X; Morris J; Brown T; Rashid A; Dancey J; Abbruzzese JL;
Institution: Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA. methomas@mdanderson.org
Journal: Cancer. 2007 Sep 1;110(5):1059-67.
Abstract URL: Click here to view abstract

17. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.

Author: Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST;
Institution: Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Journal: Clin Gastroenterol Hepatol. 2007 Sep;5(9):1100-8. Epub 2007 Jul 12.
Abstract URL: Click here to view abstract

18. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

Author: Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT;
Institution: California Pacific Medical Center, San Francisco, CA 94115, USA. gishr@sutterhealth.org
Journal: J Clin Oncol. 2007 Jul 20;25(21):3069-75.
Abstract URL: Click here to view abstract

19. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial.

Author: Zhang YJ; Liang HH; Chen MS; Guo RP; Li JQ; Zheng Y; Zhang YQ; Lau WY;
Institution: Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Rd East, Guangzhou 510060, China.
Journal: Radiology. 2007 Aug;244(2):599-607.
Abstract URL: Click here to view abstract

20. Surgical options in the treatment of hepatocellular carcinoma.

Author: Williams R; White J; Croce M; Dilawari R;
Institution: Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA. rfwillia@utmem.edu
Journal: Am Surg. 2007 Jul;73(7):658-62; discussion 662-3.
Abstract URL: Click here to view abstract

21. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.

Author: Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee do Y; Chon CY; Moon YM; Han KH;
Institution: Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Journal: Cancer. 2007 Jul 1;110(1):129-37.
Abstract URL: Click here to view abstract

22. Multiple-electrode radiofrequency ablation of hepatic malignancies: initial clinical experience.

Author: Laeseke PF; Frey TM; Brace CL; Sampson LA; Winter TC 3rd; Ketzler JR; Lee FT Jr;
Institution: Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.
Journal: AJR Am J Roentgenol. 2007 Jun;188(6):1485-94.
Abstract URL: Click here to view abstract

23. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable.

Author: Kim TH; Kim DY; Park JW; Kim YI; Kim SH; Park HS; Lee WJ; Park SJ; Hong EK; Kim CM;
Institution: Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Journal: Am J Clin Oncol. 2006 Dec;29(6):568-75.
Abstract URL: Click here to view abstract

24. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.

Author: Mazzaferro V; Romito R; Schiavo M; Mariani L; Camerini T; Bhoori S; Capussotti L; Calise F; Pellicci R; Belli G; Tagger A; Colombo M; Bonino F; Majno P; Llovet JM;
Institution: Department of Surgery, Biomedical Statistics, Pathology, National Cancer Institute of Milan and Chair of Gastroenterology, Policlinico Foundation, Department of Medicine, University of Milan, Italy. vincenzo.mazzaferro@istitutotumori.mi.it
Journal: Hepatology. 2006 Dec;44(6):1543-54.
Abstract URL: Click here to view abstract

25. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.

Author: Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP;
Institution: Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Journal: Radiology. 2007 May;243(2):509-19.
Abstract URL: Click here to view abstract

26. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.

Author: Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taieb J;
Institution: Service d'Hepato-gastro-enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France.
Journal: Cancer. 2007 Apr 1;109(7):1384-90.
Abstract URL: Click here to view abstract

27. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience.

Author: Furst G; Schulte am Esch J; Poll LW; Hosch SB; Fritz LB; Klein M; Godehardt E; Krieg A; Wecker B; Stoldt V; Stockschlader M; Eisenberger CF; Modder U; Knoefel WT;
Institution: Institute of Diagnostic Radiology, Heinrich-Heine-University of Duesseldorf, Moorenstr 5, 40225 Duesseldorf, Germany.
Journal: Radiology. 2007 Apr;243(1):171-9. Epub 2007 Feb 20.
Abstract URL: Click here to view abstract

28. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin.

Author: Nakazawa T; Kokubu S; Shibuya A; Ono K; Watanabe M; Hidaka H; Tsuchihashi T; Saigenji K;
Institution: Gastroenterology Division of Internal Medicine, Kitasato University East Hospital, 2-1-1 Asamizodai, Sagamihara, Kanagawa 228-8520, Japan. tnakazaw@kitasato-u.ac.jp
Journal: AJR Am J Roentgenol. 2007 Feb;188(2):480-8.
Abstract URL: Click here to view abstract

29. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.

Author: Lo CM; Liu CL; Chan SC; Lam CM; Poon RT; Ng IO; Fan ST; Wong J;
Institution: Centre for the Study of Liver Disease and the Department of Surgery, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. chungmlo@hkucc.hku.hk
Journal: Ann Surg. 2007 Jun;245(6):831-42.
Abstract URL: Click here to view abstract

30. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.

Author: Hasegawa K; Takayama T; Ijichi M; Matsuyama Y; Imamura H; Sano K; Sugawara Y; Kokudo N; Makuuchi M;
Institution: Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, University of Tokyo, Japan.
Journal: Hepatology. 2006 Oct;44(4):891-5.
Abstract URL: Click here to view abstract

31. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

Author: Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ;
Institution: Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China.
Journal: J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8.
Abstract URL: Click here to view abstract

32. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Author: Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C;
Institution: Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. philipp@karmanos.org
Journal: J Clin Oncol. 2005 Sep 20;23(27):6657-63.
Abstract URL: Click here to view abstract

33. Natural history of untreated nonsurgical hepatocellular carcinoma.

Author: Yeung YP; Lo CM; Liu CL; Wong BC; Fan ST; Wong J;
Institution: Department of Surgery, Kwong Wah Hospital, and Centre for the Study of Liver Disease, China.
Journal: Am J Gastroenterol. 2005 Sep;100(9):1995-2004.
Abstract URL: Click here to view abstract

34. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Author: Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB;
Institution: Memorial Sloan-Kettering Cancer Center, York, NY 10022, USA. abou-alg@mskcc.org
Journal: J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.
Abstract URL: Click here to view abstract

35. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients.

Author: Chen CH; Chang TT; Cheng KS; Su WW; Yang SS; Lin HH; Wu SS; Lee CM; Changchien CS; Chen CJ; Sheu JC; Chen DS; Lu SN;
Institution: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Journal: Liver Int. 2006 Sep;26(7):766-73.
Abstract URL: Click here to view abstract

36. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.

Author: Poh SB; Bai LY; Chen PM;
Institution: Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, and the National Yang-Ming University Taipei, Taiwan.
Journal: Am J Clin Oncol. 2005 Dec;28(6):540-6.
Abstract URL: Click here to view abstract

37. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.

Author: Eckel F; von Delius S; Mayr M; Dobritz M; Fend F; Hosius C; Schleyer E; Schulte-Frohlinde E; Schmid RM; Lersch C;
Institution: Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Germany. florian.eckel@lrz.tum.de
Journal: Oncology. 2005;69(5):363-71. Epub 2005 Nov 24.
Abstract URL: Click here to view abstract

38. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.

Author: Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW;
Institution: Division of Cancer Research, National Health Research Institutes, Ward 191 Veterans General Hospital, Taipei, and Department of Internal Medicine, Kaohsiung Medical University Hospital, Taiwan, ROC.
Journal: Cancer Chemother Pharmacol. 2006 Nov;58(5):654-64. Epub 2006 Mar 7.
Abstract URL: Click here to view abstract

39. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.

Author: Lin, S-M; Lin, C-J; Lin, C-C; Hsu, C-W; Chen, Y-C;
Institution: Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, 199 Tung Hwa North Rd, Taipei, Taiwan. lsmpaicyto@cgmh.org.tw
Journal: Gut 2005 Aug;54(8):1151-6.
Abstract URL: Click here to view abstract

40. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.

Author: Barbare, Jean-Claude; Bouche, Olivier; Bonnetain, Franck; Raoul, Jean-Luc; Rougier, Philippe; Abergel, Armand; Boige, Valerie; Denis, Bernard; Blanchi, Alain; Pariente, Alexandre; Milan, Chantal; Bedenne, Laurent;
Institution: Service d'Hepato-Gastroenterologie, Centre Hospitalier, 8 avenue Henri Adnot, 60321 Compiegne, France. jcbarbare001@ch-compiegne.rss.fr
Journal: J Clin Oncol 2005 Jul 1;23(19):4338-46.
Abstract URL: Click here to view abstract

41. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study.

Author: Huang, Guan-Tarn; Lee, Po-Huang; Tsang, Yuk-Ming; Lai, Ming-Yang; Yang, Pei-Ming; Hu, Rey-Heng; Chen, Pei-Jer; Kao, Jia-Horng; Sheu, Jin-Chuan; Lee, Cha-Ze; Chen, Ding-Shinn;
Institution: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Journal: Ann Surg 2005 Jul;242(1):36-42.
Abstract URL: Click here to view abstract